Article thumbnail
Location of Repository

Clinical features related to GM3 in patients with RA or OA. A.

By Yukinori Tsukuda (317544), Norimasa Iwasaki (317545), Naoki Seito (317546), Masashi Kanayama (317547), Naoki Fujitani (317549), Yasuro Shinohara (317551), Yasuhiko Kasahara (317553), Tomohiro Onodera (317554), Koji Suzuki (209461), Tsuyoshi Asano (317557), Akio Minami (317559) and Tadashi Yamashita (317562)


<p>Histology of RA and OA patients. Hematoxylin and eosin (HE) staining. Scale bars  = 200 µm. <b>B.</b> Quantification of total GSL glycans in human synovium (<i>n</i>  = 5 per group). <b>C.</b> Absolute and relative amounts of GM3 glycans in human synovium (<i>n</i>  = 5 per group). <b>D.</b> Quantification of GM3S mRNA in synovium and PBMCs in RA and OA patients (<i>n</i>  = 5 per group). Data shown are mean ± SEM. *<i>P</i><0.05, compared to OA patients.</p

Topics: Biochemistry, Ecology, Immunology, gm3, patients, ra
Year: 2013
DOI identifier: 10.1371/journal.pone.0040136.g002
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.